Cobratide injection vs pregabalin for moderate-to-severe acute herpes zoster neuralgia: A randomized, double-blind, double-dummy, active-controlled, multicenter exploratory trial.
Xuegang Xu, Xu Han, Xiaodong Li et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized, double-blind, double-dummy, active-controlled trial evaluated Cobratide injection versus Pregabalin for moderate-to-severe acute herpes zoster neuralgia in 80 patients aged 50-70 years. At day 28, Cobratide resulted in a mean NRS pain reduction of 6.00 compared to 5.63 for Pregabalin, with no significant difference (P = .186).
Key findings
- Cobratide injection reduced NRS pain score by 6.00, while Pregabalin reduced it by 5.63.
- No significant difference in PHN incidence: 0/27 for Cobratide vs 3/27 for Pregabalin (P = .236).
- Treatment-emergent adverse events occurred in 35.9% of Cobratide patients and 51.2% of Pregabalin patients.
Why it matters
The study highlights an alternative treatment for acute herpes zoster neuralgia, particularly in older adults who may experience adverse effects from traditional analgesics. Understanding the efficacy and tolerability of Cobratide could inform pain management strategies.
What to keep in mind
Exploratory design, small sample size, and lack of systematic collection of vaccination history and rash-onset timing limited inference.